Biogen (NASDAQ:BIIB) Insider Priya Singhal Sells 2,660 Shares

Biogen Inc. (NASDAQ:BIIB) insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Priya Singhal also recently made the following trade(s):

• On Monday, February 2nd, Priya Singhal sold 748 shares of Biogen stock. The shares were sold at an average price of $179.30, for a total transaction of $134,116.40.

Biogen Stock Performance

Shares of BIIB stock opened at $188.99 on Wednesday. The firm has a market cap of $27.74 billion, a price-to-earnings ratio of 21.45, a PEG ratio of 1.55 and a beta of 0.16. Biogen Inc. has a 52-week low of $110.04 and a 52-week high of $202.41. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The company’s 50 day moving average is $177.44 and its 200 day moving average is $157.89.

Biogen (NASDAQ:BIIB) last posted its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter in the prior year, the business earned $3.44 earnings per share. Biogen’s revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts anticipate that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Morgan Stanley set a $190.00 price target on shares of Biogen in a research report on Sunday. Wolfe Research set a $231.00 price objective on shares of Biogen in a research note on Monday. Sanford C. Bernstein restated a “market perform” rating on shares of Biogen in a research note on Monday. Royal Bank Of Canada lifted their price target on shares of Biogen from $217.00 to $233.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Oppenheimer increased their price objective on Biogen from $205.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, January 30th. Thirteen investment analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. According to MarketBeat, Biogen presently has an average rating of “Hold” and a consensus price target of $207.81.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BIIB. Privium Fund Management B.V. purchased a new stake in shares of Biogen in the second quarter worth approximately $2,666,000. Nordea Investment Management AB boosted its stake in shares of Biogen by 5.7% during the 2nd quarter. Nordea Investment Management AB now owns 125,935 shares of the biotechnology company’s stock valued at $15,810,000 after buying an additional 6,811 shares during the period. Convergence Investment Partners LLC purchased a new position in shares of Biogen during the 3rd quarter valued at $1,342,000. Pitcairn Co. acquired a new position in shares of Biogen in the second quarter worth $936,000. Finally, Fluent Financial LLC purchased a new stake in shares of Biogen during the third quarter worth $3,578,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and updated guidance — Biogen reported Q4 results and FY guidance that topped expectations (EPS and revenue beats; FY2026 EPS range of 15.25–16.25), a key driver for recent analyst upgrades and higher targets. Article Title
• Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The biologics license application for a subcutaneous formulation of Leqembi (lecanemab) was designated for priority review, which could materially expand the Alzheimer’s franchise if approved. Article Title
• Positive Sentiment: Multiple bullish analyst moves lift upside — Several firms raised price targets and/or maintained Buy ratings after the results and pipeline updates (Goldman Sachs PT raised to $231; RBC to $233; HC Wainwright to $228; Canaccord and others also raised targets), supporting multi-quarter upside expectations. Article Title
• Neutral Sentiment: Pipeline diversification headlines (lupus, SMA) — Management and coverage note advancing programs beyond Alzheimer’s, which improves long-term growth optionality but will take time to materialize. Article Title
• Neutral Sentiment: Mixed analyst stances — Several shops raised price targets but kept neutral/hold ratings (Citigroup, Piper Sandler, Wedbush, Truist), indicating disagreement on valuation even after beats. Article Title
• Neutral Sentiment: Short-interest report appears unreliable — A reported “significant increase” shows zero shares in the feed (data inconsistent); no clear short-covering pressure signaled. (internal short-interest entry)
• Negative Sentiment: Ongoing franchise pressure and execution risk — Coverage notes that legacy multiple sclerosis (MS) franchise pressures and execution on expanding Leqembi access/commercial scale remain risks that could cap near-term upside. Article Title

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.